Advancements in Triple-Negative Breast Cancer Treatment

This chapter explores the critical role of biopsies in diagnosing and guiding treatment for metastatic triple-negative breast cancer (TNBC), emphasizing both tissue and liquid biopsy approaches. It highlights the potential of therapies like enzalutamide and sasituzumab while addressing the management of adverse effects and the importance of personalized treatment strategies based on molecular characteristics. Additionally, the chapter discusses ongoing clinical trials and the effectiveness of antibody-drug conjugates in improving patient outcomes, even with low receptor expression.